Tat-PTD-modified oncolytic adenovirus driven by the SCG3 promoter and ASH1 enhancer for neuroblastoma therapy

Human Gene Therapy

Volumn 24, Issue 8, 2013, Pages 766-775

  Jin, Chuan ^a   Yu, Di ^a   Čančer, Matko ^a   Nilsson, Berith ^a   Leja, Justyna ^a   Essand, Magnus ^a  

^a UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ACHAETE SCUTE COMPLEX HOMOLOG 1; CELL PENETRATING PEPTIDE; CISPLATIN; DNA FRAGMENT; DOXORUBICIN; ETOPOSIDE; ONCOLYTIC ADENOVIRUS; PEPTIDES AND PROTEINS; SECRETOGRANIN III; UNCLASSIFIED DRUG; VINCRISTINE;

ANIMAL CELL; ARTICLE; CANCER GENE THERAPY; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; NEUROBLASTOMA; NEUROBLASTOMA CELL; NONHUMAN; SEROTYPE; TRANSGENE; TUMOR GROWTH; VIRUS CAPSID; XENOGRAFT;

ADENOVIRIDAE; ADENOVIRUS E1A PROTEINS; ANIMALS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CELL LINE, TUMOR; CELL SURVIVAL; CELL-PENETRATING PEPTIDES; ENHANCER ELEMENTS, GENETIC; FEMALE; GENETIC THERAPY; HUMANS; MICE; MICE, NUDE; NEUROBLASTOMA; ONCOLYTIC VIRUSES; PROMOTER REGIONS, GENETIC;

EID: 84882419012     PISSN: 10430342     EISSN: 15577422     Source Type: Journal    
DOI: 10.1089/hum.2012.132     Document Type: Article

References (31)

1. Chen, H., Biel, M.A., Borges, M.W., et al. (1997). Tissue-specific expression of human achaete-scute homologue-1 in neuroendocrine tumors: Transcriptional regulation by dual inhibitory regions. Cell Growth Differ. 8, 677-686.
2. Cheng, W.S., Kraaij, R., Nilsson, B., et al. (2004). A novel TARPpromoter- based adenovirus against hormone-dependent and hormone-refractory prostate cancer. Mol. Ther. 10, 355-364.
3. Danielsson, A., Dzojic, H., Nilsson, B., and Essand, M. (2008). Increased therapeutic efficacy of the prostate-specific oncolytic adenovirus Ad[I/PPT-E1A] by reduction of the insulator size and introduction of the full-length E3 region. Cancer Gene Ther. 15, 203-213.
4. Essand, M. (2013). Virotherapy of neuroendocrine tumors. Neuroendocrinology 97, 26-34.
5. Garcia-Castro, J., Alemany, R., Cascallo, M., et al. (2010). Treatment of metastatic neuroblastoma with systemic oncolytic virotherapy delivered by autologous mesenchymal stem cells: An exploratory study. Cancer Gene Ther. 17, 476-483.
6. Gestblom, C., Grynfeld, A., Ora, I., et al. (1999). The basic helix- loop-helix transcription factor dHAND, a marker gene for the developing human sympathetic nervous system, is expressed in both high- and low-stage neuroblastomas. Lab. Invest. 79, 67-79.
7. He, T.C., Zhou, S., Da Costa, L.T., et al. (1998). A simplified system for generating recombinant adenoviruses. Proc. Natl. Acad. Sci. U.S.A. 95, 2509-2514.
8. Hoehner, J.C., Gestblom, C., Hedborg, F., et al. (1996). A developmental model of neuroblastoma: Differentiating stromapoor tumors' progress along an extra-adrenal chromaffin lineage. Lab. Invest. 75, 659-675.
9. Hoti, N., Chowdhury, W., Hsieh, J.T., et al. (2006). Valproic acid, a histone deacetylase inhibitor, is an antagonist for oncolytic adenoviral gene therapy. Mol. Ther. 14, 768-78.
10. Iwasaki, I., Sugiyama, H., Kanazawa, S., and Hemmi, H. (2002). Establishment of cisplatin-resistant variants of human neuroblastoma cell lines, TGW and GOTO, and their drug cross-resistance profiles. Cancer Chemother. Pharmacol. 49, 438-444.
11. Kanai, R., Wakimoto, H., Cheema, T., and Rabkin, S.D. (2010). Oncolytic herpes simplex virus vectors and chemotherapy: Are combinatorial strategies more effective for cancer? Future Oncol. 6, 619-634.
12. Kushner, B.H., Laquaglia, M.P., Bonilla, M.A., et al. (1994). Highly effective induction therapy for stage 4 neuroblastoma in children over 1 year of age. J. Clin. Oncol. 12, 2607-2613.
13. Leja, J., Dzojic, H., Gustafson, E., et al. (2007). A novel chromogranin-A promoter-driven oncolytic adenovirus for midgut carcinoid therapy. Clin. Cancer Res. 13, 2455-2462.
14. Leja, J., Nilsson, B., Yu, D., et al. (2010). Double-detargeted oncolytic adenovirus shows replication arrest in liver cells and retains neuroendocrine cell killing ability. PLoS One 5, e8916.
15. Li, L., Hung, A.C., and Porter, A.G. (2008). Secretogranin II: A key AP-1-regulated protein that mediates neuronal differentiation and protection from nitric oxide-induced apoptosis of neuroblastoma cells. Cell Death Differ. 15, 879-888.
16. London, W.B., Castleberry, R.P., Matthay, K.K., et al. (2005). Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children's Oncology Group. J. Clin. Oncol. 23, 6459-6465.
17. Maris, J.M. (2010). Recent advances in neuroblastoma. N. Engl. J. Med. 362, 2202-2211.
18. Modak, S., and Cheung, N.K. (2010). Neuroblastoma: Therapeutic strategies for a clinical enigma. Cancer Treat. Rev. 36, 307-317.
19. Monclair, T., Brodeur, G.M., Ambros, P.F., et al. (2009). The International Neuroblastoma Risk Group (INRG) staging system: An INRG Task Force report. J. Clin. Oncol. 27, 298-303.
20. Ozawa, H., and Takata, K. (1995). The granin family - its role in sorting and secretory granule formation. Cell Struct. Funct. 20, 415-420.
21. Pesonen, S., Helin, H., Nokisalm, P., et al. (2010). Oncolytic adenovirus treatment of a patient with refractory neuroblastoma. Acta Oncol. 49, 117-119.
22. Portela-Gomes, G.M., Grimelius, L., and Stridsberg, M. (2010). Secretogranin III in human neuroendocrine tumours: A comparative immunohistochemical study with chromogranins A and B and secretogranin II. Regul. Pept. 165, 30-35.
23. Rein, D.T., Volkmer, A., Bauerschmitz, G., et al. (2012). Combination of a MDR1-targeted replicative adenovirus and chemotherapy for the therapy of pretreated ovarian cancer. J. Cancer Res. Clin. Oncol. 138, 603-610.
24. Rong, Y.P., Liu, F., Zeng, L.C., et al. (2002). Cloning and characterization of a novel human secretory protein: Secretogranin III. Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai) 34, 411-417.
25. Stanton, R.J., McSharry, B.P., Armstrong, M., et al. (2008). Reengineering adenovirus vector systems to enable highthroughput analyses of gene function. Biotechniques 45, 659-662, 664-668.
26. Watt, F., Watanabe, R., Yang, W., et al. (2007). A novel MASH1 enhancer with N-myc and CREB-binding sites is active in neuroblastoma. Cancer Gene Ther. 14, 287-296.
27. Wodrich, H., Guan, T., Cingolani, G., et al. (2003). Switch from capsid protein import to adenovirus assembly by cleavage of nuclear transport signals. EMBO J. 22, 6245-6255.
28. Yan, X.D., Li, M., Yuan, Y., et al. (2007). Biological comparison of ovarian cancer resistant cell lines to cisplatin and Taxol by two different administrations. Oncol. Rep. 17, 1163-1169.
29. Yasui, T., Ohuchida, K., Zhao, M., et al. (2011). Adenoviral therapy is more effective in gemcitabine-resistant pancreatic cancer than in gemcitabine-sensitive cells. Anticancer Res. 31, 1279-1287.
30. Yu, D., Jin, C., Leja, J., et al. (2011). Adenovirus with hexon Tatprotein transduction domain modification exhibits increased therapeutic effect in experimental neuroblastoma and neuroendocrine tumors. J. Virol. 85, 13114-13123.
31. Yu, D., Jin, C., Ramachandran, M., et al. (2013). Adenovirus serotype 5 vectors with Tat-PTD modified hexon and serotype 35 fiber show greatly enhanced transduction capacity of primary cell cultures. PLoS One 8, e54952.